Amgen posts results for rocatinlimab AD trial, daxdilimab myositis study; mCRPC trial terminated

Amgen's clinical trial registry saw updates across three programs spanning atopic dermatitis, myositis, and prostate cancer.

• Rocatinlimab (AMG 451), a Phase 3 trial in adolescents with moderate-to-severe atopic dermatitis called "ROCKET-ASTRO," is completed with primary completion on 2025-02-27 and study completion on 2025-11-25¹. Results were first posted 2026-08-28, and the trial enrolled 532 participants¹, with a primary outcome of the number of participants achieving vIGA-AD 1 response with only barely perceptible erythema or vIGA-AD 0 response at Week 24¹.
• Daxdilimab, a Phase 2 trial in dermatomyositis or anti-synthetase inflammatory myositis, is completed, with the primary efficacy objective being to evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24². Results were first posted 2026-08-25; the study enrolled 12 participants².
• A master protocol evaluating acapatamab and other therapies in metastatic castration-resistant prostate cancer is listed as terminated because Amgen made a business decision to discontinue all AMG 160 clinical trials, a decision the company said was not related to safety³. The study enrolled 55 participants³ and results were first posted 2026-08-26.